Latest From FibroGen Inc.
Confusion over top-line pooled cardiovascular Phase III safety data on anemia therapy roxadustat caused shares in AstraZeneca and FibroGen to slide on 9 May, but analysts later said the negative reaction was overdone.
Switzerland’s leader in iron deficiency therapies wants to add new products in this and adjacent therapeutic areas, as strong revenue growth in 2018 backs its strategy of concentrating its efforts on the pharmaceuticals business.
Lying underneath AstraZeneca’s stellar quarter were the growth engines of emerging markets and China, where novel drugs, especially in oncology, delivered. But mounting pricing pressures and a massive new centralized bidding process are clouds on the horizon.
Despite multiple adverse factors including a leadership shakeup and the departure of its top regulator, the China FDA seemed determined to refresh itself after a name change and to speed up new drugs to market.
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Hepatic (Liver)
- Musculoskeletal & Connective Tissue Disorders
- Renal System
- North America
- Parent & Subsidiaries
- FibroGen Inc.
- Senior Management
Thomas B Neff, Chmn. & CEO
Pat Cotroneo, VP, Fin. & CFO
David M Dimmick, MD, VP, Quality
R. Wayne Frost, VP, RA
Elias Kouchakji, MD, VP, Clinical Dev and Drug Safety
AI Lin, MD, PhD, VP, Drug Dev.
Peony K Yu, CMO
- Contact Info
Phone: (415) 978-1200
409 Illinois St.
San Francisco, CA 94158
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.